Introduction: There is evidence suggesting that certain subgroups of people who use tobacco do not receive tobacco pharmacology as consistently as others. Methods: This retrospective, cohort study examined the trend in the use of cessation pharmacotherapy from 2004 to 2013 using Veterans Health Administration (VHA) administrative data. Among Veterans who used tobacco in the fiscal year (FY) 2011 and had not received pharmacotherapy in the prior year, multivariable Cox regression was used to assess the independent associations between patient clinical and demographic characteristics and pharmacotherapy initiation in the 6-months follow-up period. Results: Smoking cessation pharmacotherapy in the VHA increased from 13.8% in 2004 to 25.6% in 2013. In 2011, Veterans (N = 838 309) who were more likely to newly receive pharmacotherapy included those with psychiatric disorders (depression, bipolar disorder, non-alcohol substance use disorder, other anxiety, and post-traumatic stress disorder), chronic pulmonary disease, peripheral vascular disorders, and younger Veterans (adjusted rate ratios (ARRs) ranged from 1.03 to 1.92, all p < .001). Veterans less likely to receive pharmacotherapy were those with schizophrenia or other psychosis, males, Hispanics, and those with a medical condition (uncomplicated diabetes, uncomplicated hypertension, fluid and electrolyte disorders, cardiac arrhythmia, valvular disease, hypothyroidism, acquired immunodeficiency syndrome/human immunodeficiency virus, deficiency anemia, renal failure, paralysis, coagulopathy, metastatic cancer, and other neurological disorders) (ARRs ranged from 0.74 to 0.93, all p < .001).
Introduction
Although tobacco cessation guidelines recommend pharmacotherapy for those trying to quit, 1,2 only about one-third of quit attempts are supported by pharmacotherapy. 3 Demographic differences are associated with pharmacotherapy use for tobacco cessation. For example, those over age 65 who smoke are less likely to attempt to quit, 4 but quit attempts are more likely to be supported by pharmacotherapy. 3 Women are more likely to use cessation aids than men. 5, 6 Non-Hispanic Whites are more likely to use tobacco cessation pharmacotherapy than those who are African-American, 5, 7 Hispanic, 3, 6, 8 or Asian. 3 Tobacco cessation pharmacotherapy is used more by patients covered by private insurance or a military health plan than by those covered by Medicare or Medicaid. 9, 10 Uninsured tobacco users are much less likely to use a cessation aid. 3 Quit attempts are less common among those with greater nicotine dependence, 11 yet quit attempts among those with nicotine dependence are more likely to include pharmacotherapy use. 10, 11 Given that most information on pharmacotherapy use comes from population surveys that gather limited information on respondents' health, there is limited information on the influence of psychiatric or chronic medical illnesses on the use of tobacco cessation pharmacotherapy and the available information is contradictory. For example, Veterans who use tobacco and are limited by disability or serious psychological distress are more likely to use cessation aids to support quitting, 3 but poor physical health was not associated with any significant difference in use of cessation aids. 6 Furthermore, it has been previously reported that those with chronic obstructive lung disease were more likely to be offered smoking cessation therapies, 12 but it is not clear if this resulted in greater use of smoking cessation aids. Additional information would be valuable to identify groups that may need special help in obtaining tobacco pharmacotherapy to support a quit attempt.
The Veterans Health Administration (VHA) provides care to a large number of tobacco users with medical and psychiatric comorbidities. Similar to the general population, tobacco use rates in the VHA are high among those with psychiatric and substance abuse disorders. To increase the availability of tobacco cessation pharmacotherapy among Veterans, in 2003 the VHA implemented VHA directive 2003-042 (updated in 2008 and 2014) called the National Smoking and Tobacco Use Cessation Program, which stated that "smoking cessation medications need to be made available to all smokers interested in quitting, regardless of whether or not the patient is willing to attend a smoking cessation program."
To determine the initiation of pharmacotherapy for tobacco cessation in the VHA, the specific aims of this study were to: (1) evaluate trends in tobacco cessation pharmacotherapy among Veterans who currently use tobacco; and (2) determine the demographic and clinical characteristics of Veterans who initiated a new episode of tobacco cessation pharmacotherapy in the VHA.
Methods

Design
This retrospective cohort study identified trends in tobacco cessation pharmacotherapy dispensed by the VHA between 2004 and 2013 and characteristics of Veterans who currently used tobacco that did versus did not initiate pharmacotherapy in 2011. All years refer to the federal fiscal year (FY), which ends on September 30. Patient demographic and clinical data were abstracted from the VHA Corporate Data Warehouse (CDW), the national repository of VHA electronic medical records (EMR). Tobacco use status data were obtained from the health factors (clinical reminder) dataset. Tobacco cessation pharmacotherapy outpatient prescription data were abstracted from the VHA Pharmacy Benefits Management system. This study was approved by the Institutional Review Boards (IRBs) at both the VA Ann Arbor Healthcare System and the VA Palo Alto Health Care System. The IRB approved only retrospective use of data from the time of IRB approval, thus the study time frame ends on the date just prior to the 2013 IRB approvals.
Sample
Included in the study sample to evaluate trends in the rate of tobacco pharmacotherapy were Veterans currently using tobacco at any time during each fiscal year in the health factor data. To determine characteristics of Veterans who initiated a new episode of tobacco cessation pharmacotherapy, FY11 current tobacco user sample was used after excluding Veterans who: (1) did not have at least one visit in the prior 12 months (and thus had no utilization data); and/or, (2) already received pharmacotherapy in the 12 months prior to the date of their last tobacco use assessment (to focus on initiation of treatment). In FY11, 13.2% (N = 765 865) did not have health factor data available.
Full details of the methods used to identify current smokers are available elsewhere. [13] [14] [15] In brief, VHA guidelines require at least one assessment of all patients, including younger Veterans initiating care at VA and annual assessments thereafter of current and former tobacco users. However, those who have quit for at least 7 years or those identified as life-time never users do not require annual assessments, although many of these individuals are still assessed periodically. Screening results are recorded as 40-character text entry with the date and time of the entry and a patient identifier. Entries were assigned to standard categories of current user of tobacco, never user, and former users characterized by duration of quit: within the last year, 1-7 years previously, or >7 years previously.
Multiple entries on a single date were resolved by using the most specific entry; for example, entries of "former smoker" and "quit <1 year" were assigned to the category former user that had quit within the last year. Assessments included use of smokeless tobacco, but not electronic nicotine delivery systems. An earlier study found tobacco use status in this dataset to be highly correlated with selfreported status. 15 
Procedures
Initiation of pharmacotherapy was assessed in the 6 months following assessment as current tobacco user. Observations were censored on the date of death or at 6 months after the assessment if pharmacotherapy was not dispensed. Predictors of the use of tobacco pharmacotherapy were studied in Veterans identified as currently using tobacco at the time of their last assessment in 2011. This study had access to data through 2013, so 2011 is the most recent year of data that could provide a cohort of Veterans who were currently using tobacco to study treatment initiation during a follow-up period of 6 months and to follow for another 18 months after treatment initiation for a companion paper to study treatment effectiveness using the same cohort of Veterans. Comorbidities were determined from utilization data in the 12-month period prior to the tobacco assessment in FY11.
Measures
Outcome Variable
The dependent variable was initiation of tobacco cessation pharmacotherapy, including nicotine replacement therapy (NRT), bupropion, and varenicline. Since bupropion can be prescribed for purposes other than tobacco cessation, bupropion was considered to be intended for tobacco cessation if the prescription was labeled as being for smoking cessation or if it was prescribed at a dose of 300 mg per day, the dosage approved by the Food and Drug Administration (FDA) for smoking cessation. Lower dosages of bupropion, typically used for depression, but not for smoking cessation, were excluded. However, because the higher dosage typically prescribed for tobacco cessation can also be prescribed for depression, a sensitivity analysis was conducted excluding bupropion as described further below. Veterans were considered to have received multiple medications if two or more drugs (NRT, bupropion, or varenicline) were received within the same fiscal year. For example, those currently using tobacco who were prescribed NRT in January and bupropion in August or at the same time were classified in the NRT and bupropion group.
Predictor Variables/Covariates
Candidate predictors of tobacco pharmacotherapy included age, sex, race, ethnicity, as well as medical, psychiatric, and substance abuse comorbidities. Standard sets of diagnostic codes were used to identify medical conditions (yes/no) (Elixhauser) 16 and psychiatric and substance abuse comorbidities (yes/no). [17] [18] [19] [20] [21] To control for the effects of unmeasured facility-level differences in the use of pharmacotherapy and location-specific differences affecting tobacco use, such as tobacco tax rates and smoking regulations, indiciator variables were created for the facilities where the tobacco use assessments took place.
Statistical Analysis
Annual prevalence of tobacco pharmacotherapy was calculated by dividing the number of Veterans who used tobacco and also used pharmacotherapy by the total number of Veterans who currently used tobacco for each fiscal year from 2004-2013. Trends in VHA pharmacotherapy prescribed were determined by identifying individuals who received at least one outpatient prescription of tobacco pharmacotherapy. Trends in the types of pharmacotherapy received were determined by assigning pharmacotherapy recipients to mutually exclusive groups defined by single and by multiple pharmacotherapy types used in the same year.
Time to treatment initiation was calculated as the number of days between the assessment of tobacco use and the first date that tobacco pharmacotherapy was dispensed, and the time was censored at 6 months. The rate of treatment initiation was calculated as the number of Veterans who used tobacco and initiated pharmacotherapy divided by the total time eligible for treatment initiation during the 6-month follow-up period.
Cox regression models were used to estimate the unadjusted and adjusted rate ratio of time to pharmacotherapy initiation. Unadjusted rate ratios (RRs) were estimated for each potential predictor using separate Cox regression models with each predictor, adjusting for parent facility as fixed effects. Adjusted rate ratios (ARRs) were estimated using a Cox regression model that included all demographic and clinical predictors and facility as fixed effects. ARRs represent the independent association between a given characteristic and pharmacotherapy initiation, ie, risk of initiation associated in those with the characteristic relative to those without the characteristic.
Two sensitivity analyses were conducted for this study. Since 6.3% of the cohort was missing information on race or ethnicity and were excluded from the Cox model for the estimation of ARR, the first sensitivity analysis included the observations with missing race or ethnicity, but excluded race and ethnicity from the model. To address the fact that higher doses of bupropion may be prescribed for both smoking cessation therapy and depression, the second sensitivity analysis was conducted excluding bupropion as a pharmacotherapy treatment (that is, pharmacotherapy included NRT and varenicline only) and controlling for bupropion use in the prior year. For this, the cohort was limited to Veterans who were current tobacco users who had not received NRT or varenicline in the 12 months prior to the date of their tobacco assessment.
Results
Trends in Smoking Cessation Pharmacotherapy
Among Veterans who used tobacco, pharmacotherapy use increased from 13.8% in 2004 to 26.8% in 2008, with little change thereafter; in 2013, 25.6% of Veterans who used tobacco received pharmacotherapy (Table 1 ). Figure 1 displays trends in the specific types of pharmacotherapy prescribed among persons identified as currently using tobacco. In 2013, 14.9% of Veterans who were currently using tobacco received NRT only, 6.2% received bupropion only, 3.2% received both NRT and bupropion in the same year, and 0.9% received varenicline only. Varenicline monotherapy prevalence peaked at 4.1% in FY 2008, followed by a sudden decline.
Patient-Level Factors Associated with Treatment Initiation
There were 1 065 146 Veterans identified as tobacco users at their last assessment in fiscal year 2011 and had a visit during the prior year. Of these, 226 837 (21.3%) were excluded as they had received pharmacotherapy in the preceding 12 months, leaving a final cohort of 838 309 for the study. During the 6-month follow-up period, 14 758 (1.8%) were censored by death and 105 758 (12.6%) initiated tobacco pharmacotherapy (NRT, bupropion, or varenicline). Of those who initiated pharmacotherapy, the average time from the clinical reminder assessment to pharmacology treatment was 1.3 months.
The rate of treatment initiation was 14.2 per 100 follow-up periods (of 6 months). The rate was higher than the proportion initiating treatment, as the average follow-up period was less than 6 months (5.4 months). This is because those Veterans who initiated treatment or died during the follow-up period were eligible for initiating treatment for less than the full 6 months of follow-up.
The rates of treatment initiation per 100 follow-up periods for patients of different characteristics are presented in Table 2 . The table also presents RRs and ARRs for treatment initiation associated with various patient characteristics. For example, for every 100 6-month periods of treatment eligibility, 18.0 Veterans who used tobacco and had depression initiated treatment compared to 13.0 of those without depression. Veterans who used tobacco and had depression had an unadjusted RR of 1.37 and an ARR of 1.22 (95% confidence interval (CI) = 1.20 to 1.24) compared to Veterans who used tobacco and did not have depression.
In addition to depression, psychiatric diagnoses that were associated with higher rate of initiating pharmacotherapy included bipolar disorder (ARR = 1.13, 95% CI = 1.10 to 1.16), post-traumatic stress disorder (PTSD) (ARR = 1.03, 95% CI = 1.01 to 1.05), and other anxiety disorder (ARR = 1.03, 95% CI = 1.02 to 1.05). On the other hand, Veterans with schizophrenia/schizoaffective disorder (ARR = 0.74, 95% CI = 0.71 to 0.77) and other psychoses (ARR = 0.90, 95% CI = 0.85 to 0.95) had significantly lower use of pharmacotherapy than Veterans without these diagnoses. Veterans with non-alcohol substance use disorder were more likely to initiate pharmacotherapy than those without this diagnosis (ARR = 1.06, 95% CI = 1.04 to 1.09). However, there was no association between a diagnosis of alcohol use disorder and pharmacotherapy initiation. From multivariable Cox regression model for treatment initiation with all listed variables as predictors and controlling for facilities (using dummy variables for parent facilities); N = 785 091 because those with missing race/ethnicity were not included in the model. **p < .001; *p < .05 Table 2 .
Continued
Veterans with chronic pulmonary disease who used tobacco were significantly more likely to initiate pharmacotherapy (ARR = 1.28, 95% CI = 1.26 to 1.31), as were those with peripheral vascular disorders (ARR = 1.22, 95% CI = 1.19 to 1.25). Several other comorbid medical conditions were associated with lower rates of treatment initiation, including uncomplicated hypertension, uncomplicated diabetes, cardiac arrhythmia, HIV/AIDS, renal failure, and metastatic cancer (all ARR's significantly less than 1.00, p < .001). Unadjusted and adjusted associations were consistent for most conditions, with adjusted RR attenuated toward the null. The single exception was chronic pulmonary disease, where the adjusted RR of 1.28 was larger than the unadjusted RR of 1.13.
Younger Veteran tobacco users initiated pharmacotherapy at nearly twice the rate of those aged 65 and older (ARR = 1.92, 95% CI = 1.87 to 1.96; ARR = 1.91, 95% CI = 1.87 to 1.96; ARR = 1.62, 95% CI = 1.59 to 1.65 for ages 18-44, 45-54, 54-64 years old respectively). Males who used tobacco were significantly less likely than females to initiate treatment (ARR = 0.92, 95% CI = 0.90 to 0.95). Hispanics were less likely than non-Hispanics to initiate treatment (ARR = 0.89, 95% CI = 0.85 to 0.92). There were no significant differences in treatment initiation between African-American and White Veterans who used tobacco.
The sensitivity analysis that excluded race and ethnicity from the model showed similar results. Veterans who currently used tobacco that were significantly more likely to receive pharmacotherapy included those with most psychiatric disorders, chronic pulmonary disease, peripheral vascular disorders, and younger tobacco users (ARRs ranged from 1.03 to 1.95, all p < .001). Veterans who used tobacco that were significantly less likely to receive pharmacotherapy were males, Hispanics, those with other psychosis or schizophrenia and those with most medical conditions (ARR's ranged from 0.73 to 0.93, all p < .001). The sensitivity analysis that excluded bupropion as pharmacotherapy treatment also showed similar results. Most psychiatric diagnose (depression, non-alcohol substance abuse disorder, bipolar disorder, schizophrenia, other psychosis) that showed positive associations remained significant. Both PTSD and other anxiety, which showed small significant positive associations with pharmacotherapy initiation, were not significant in the sensitivity analysis. Most medical conditions, Hispanic ethnicity, and male sex also remained negatively associated with pharmacotherapy in the sensitivity analysis, with the addition of complicated hypertension.
Discussion
The findings from this study indicated that Veterans who use tobacco and have psychiatric comorbidities (ie, depression, bipolar disorder, PTSD, and other anxiety disorder) were more likely to receive cessation pharmacotherapy from VHA compared with individuals who used tobacco without such disorders. Previous populationbased studies have found that individuals with mental illnesses are over twice as likely to use tobacco and are less likely to quit than those without a mental illness. [22] [23] [24] Over the past decade and a half, smoking rates among those with mental illness have also declined less than those in the general population without mental illness. 25 Consequently those who smoke and have psychiatric comorbidities have been designated as a public health priority group 26 and the present findings of greater tobacco pharmacotherapy initiation among this group may be reflective of this increased awareness. Moreover, behavioral health providers may be more comfortable initiating treatment related to mental health and substance use.
Nonetheless, those diagnosed with schizophrenia/schizoaffective disorder and other psychoses were less likely to receive treatment, despite evidence that pharmacotherapy can help those with schizophrenia to quit. 27, 28 This is consistent with recent literature indicating that persons with serious mental illnesses have lower rates of tobacco treatment utilization compared to the general population. 29 Moreover, there may be concerns that these patients might suffer adverse psychiatric events due to nicotine withdrawal. 30 Given that there is a direct link between tobacco use and many types of pulmonary diseases, similar to another study, 12 treatment rates were higher in tobacco users with chronic pulmonary disease. Tobacco treatment rates in this study were also high among those with peripheral vascular disorders. However, treatment initiation was significantly lower in the presence of most other comorbid medical conditions (including uncomplicated hypertension, uncomplicated diabetes, cardiac arrhythmia, HIV/AIDS, renal failure, and metastatic cancer). Medical care providers often do not provide smoking cessation services [31] [32] [33] perhaps because they are too busy attending to the immediate medical needs of patients, perceive the patient as not motivated, do not want to make the patient feel guilty, perceive a risk of alienating patient, perceive that it will not make a difference in a patient's prognosis, perceive a lack of recognition for providing these services, have not been trained, and lack of time. [34] [35] [36] [37] [38] [39] Since continued tobacco use has been shown to exacerbate many of these comorbidities, reaching undertreated subgroups may increase cessation outcomes.
Other studies have found younger persons are more likely to engage in a quit attempt, 4 yet less likely to quit by using pharmacotherapy, 3, 5 and similarly, this study found much higher rates of treatment initiation in younger Veterans. Females were more likely to initiate pharmacotherapy than males, perhaps because it is more challenging for women to quit smoking than men due to their different responses to nicotine, lack of social support, fear of weight gain, depression, and hormones. 40 Hispanic Veterans who use tobacco were less likely to initiate treatment than non-Hispanics, a finding that is consistent with low utilization for Hispanics documented in other studies. 3, 6, 8 Unlike other studies, 41, 42 there was no differential treatment initiation among Blacks compared to Whites.
Similar to a prior paper, 43 tobacco pharmacotherapy use increased from 2004 to in 2008, with little change thereafter. During 2013, the VHA provided tobacco pharmacotherapy to 25.6% of current Veterans who use tobacco and, while not directly comparable, 18.7% of US residents who consume tobacco used pharmacotherapy in 2015. 3 Although rates of pharmacotherapy in the VHA have increased substantially, much higher rates may be achievable. For example, annual pharmacotherapy rate of 33.7% was achieved in patients of health maintenance organizations participating in the clinical trials network of the National Cancer Institute. 44 Pharmacotherapy use in VHA increased the most between 2003 and 2004 likely due to the policy that extended pharmacotherapy to Veterans not enrolled in a tobacco cessation program, 45 although policies such as changes in performance measures related to treating tobacco use 46 and the elimination of co-payment for smoking cessation counseling, may have also played a role. 43 However, treatment reached a plateau in 2008, when 26% of Veterans who use tobacco received pharmacotherapy. This trend is similar to trends observed in the US population as a whole, as the use of cessation aids among US residents who use tobacco attempting to quit increased between 2000 and 2005, with no further increases in 2010 to 2015.
The VHA predominantly used NRT as its pharmacotherapy for tobacco cessation, although it also commonly used bupropion, and varenicline was a distant third. In the overall U.S. population, people who use tobacco cessation aids most often used NRT, but a 2015 survey found 7.9% of people who smoke used varenicline compared to 2.7% who used bupropion. 3 Varenicline monotherapy use in VHA peaked at 4.1% in FY 2008, followed by a sudden decline after a boxed warning was issued by the FDA in 2009 regarding reports of changes in behavior such as hostility, agitation, depressed mood, and suicidal thoughts or actions. 47 Due to the large number of Veterans at the VHA who experience psychiatric comorbidities and restrictions on use within VHA due to the boxed warning, it appears that VHA providers decreased their use of varenicline dramatically following the 2009 warning. Recently, the FDA terminated the boxed warning, but maintained a warning and precaution for neuropsychiatric adverse events in the package labeling. Along with the change in labeling, the VHA changed prescribing criteria for varenicline to allow for wider access. It will be interesting to determine if these changes will affect the trend in prescribing in the future.
Strengths and Limitations of the Study
This study used EMR data to determine tobacco cessation treatment initiation among a large number of Veterans who used tobacco, but the data did not distinguish among the different types of tobacco use, although studies have shown that the vast majority are cigarette smokers. 48 As such, the EMR did not collect information about electronic nicotine delivery systems used by Veterans or related treatment, so no assumptions can be made as to the implications of these devices while receiving pharmacotherapy for treating nicotine dependence. As described in a prior report, 13 there are limitations to the use of health factor data including clinicians may not perform or record a tobacco assessment, intention to quit is not recorded, never users and those quit for over 7 years are not reassessed and may be missed, the non-standardization of health factor data (categories and frequency of use) across facilities, and the improving use of health factor data over time (which is why we only looked at the most recent data that we had available).
This study could determine if pharmacotherapy was prescribed and dispensed, but there was no way to know whether the pharmacotherapy was actually used as directed. The study may understate the true rate of pharmacotherapy use by VHA patients, as it does not include medications received over-the-counter or from other sources. Although dose, dosage forms, and prescription labeling were used to distinguish use of bupropion for tobacco cessation versus psychiatric conditions, the exact intent of the ordering physician could not always be determined; however a sensitivity analysis excluding bupropion produced similar results. While the study was able to determine whether multiple types of cessation medications were dispensed in the same year, it did not determine the true extent of combination therapies (ie, those prescribed simultaneously to enhance cessation). The analyses in this study (and other prior similar studies) did not include second line pharmacological agents (ie, nortriptyline or clonidine) because they are not typically used for the purpose of smoking cessation and it would be difficult to decipher whether they were used for smoking cessation or their other more common indications.
While excluding those on tobacco cessation pharmacotherapy in the prior year was the only way to establish and follow new users, these exclusions may have differed from the inclusions. The study did not control for number of visits and frequent users may have greater opportunity for tobacco assessment and treatment, although number of visits is likely to be correlated with selected comorbid conditions and obscure the results. The fixed-effects model may not have fully controlled for geographic specific differences in tobacco taxes, regulation of tobacco use, and availability of pharmacotherapy.
Conclusion
Since the implementation of VHA directive 2003-042, National Smoking and Tobacco Use Cessation Program, the VHA has substantially increased tobacco cessation pharmacotherapy, which plateaued at about 26% in 2008. Moreover, the VHA has substantially increased pharmacotherapy for tobacco cessation among patients with psychiatric conditions, a group at high risk for premature death due to tobacco use. 49 The benefits of this policy implementation may be starting to materialize. While tobacco use rates among VHA users were higher than U.S. population rates in the past, the rates are similar now (about 19%) 50 and recent unpublished VHA data suggests that rates may be declining even further. However, initiation of pharmacotherapy for tobacco cessation among those with medical comorbidities (and some psychiatric and demographic subgroups) is lacking. Efforts need to focus on increasing tobacco cessation pharmacotherapy among these underserved subgroups.
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